European Pricing Coalition Gathers Momentum
Executive Summary
A coalition of small EU countries that want to wield collective bargaining power to negotiate lower drug prices is growing, signaling a growing appetite in Europe for combined action on pricing and affordability. If the project succeeds, companies could benefit from submitting their products through a single process to reach multiple markets, but at the risk of a significant price reduction in multiple countries.
You may also be interested in...
First Benelux Joint Pricing and Reimbursement Pilot Fails Over Vertex’ Orkambi
The first pilot for the Benelux joint pricing and reimbursement process has failed. Negotiations between Vertex and the ministries of health in Belgium and the Netherlands have ended with no agreement on price for cystic fibrosis drug Orkambi.
"Crazy" European Orphan Drug Pricing System Has To End
Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.